Patrick Flume to Chloride Channel Agonists
This is a "connection" page, showing publications Patrick Flume has written about Chloride Channel Agonists.
Connection Strength
1.599
-
Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. Chest. 2021 10; 160(4):1232-1240.
Score: 0.740
-
Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Ann Am Thorac Soc. 2018 08; 15(8):897-902.
Score: 0.606
-
Treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2020 11; 26(6):679-684.
Score: 0.177
-
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713.
Score: 0.040
-
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 01; 17(1):83-88.
Score: 0.035